Moutaftsi Magdalini, Bui Huynh-Hoa, Peters Bjoern, Sidney John, Salek-Ardakani Shahram, Oseroff Carla, Pasquetto Valerie, Crotty Shane, Croft Michael, Lefkowitz Elliot J, Grey Howard, Sette Alessandro
Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA.
J Immunol. 2007 Jun 1;178(11):6814-20. doi: 10.4049/jimmunol.178.11.6814.
Recent studies have defined vaccinia virus (VACV)-specific CD8(+) T cell epitopes in mice and humans. However, little is known about the epitope specificities of CD4(+) T cell responses. In this study, we identified 14 I-A(b)-restricted VACV-specific CD4(+) T cell epitopes by screening a large set of 2146 different 15-mer peptides in C57BL/6 mice. These epitopes account for approximately 20% of the total anti-VACV CD4(+) T cell response and are derived from 13 different viral proteins. Surprisingly, none of the CD4(+) T cell epitopes identified was derived from VACV virulence factors. Although early Ags were recognized, late Ags predominated as CD4(+) T cell targets. These results are in contrast to what was previously found in CD8(+) T cells responses, where early Ags, including virulence factors, were prominently recognized. Taken together, these results highlight fundamental differences in immunodominance of CD4(+) and CD8(+) T cell responses to a complex pathogen.
近期研究已在小鼠和人类中确定了痘苗病毒(VACV)特异性CD8(+) T细胞表位。然而,对于CD4(+) T细胞应答的表位特异性却知之甚少。在本研究中,我们通过在C57BL/6小鼠中筛选一大组2146种不同的15肽,鉴定出14个I-A(b)限制性VACV特异性CD4(+) T细胞表位。这些表位约占总抗VACV CD4(+) T细胞应答的20%,且来源于13种不同的病毒蛋白。令人惊讶的是,所鉴定出的CD4(+) T细胞表位均非来源于VACV毒力因子。尽管早期抗原被识别,但晚期抗原作为CD4(+) T细胞靶标占主导地位。这些结果与先前在CD8(+) T细胞应答中所发现的情况形成对比,在CD8(+) T细胞应答中,包括毒力因子在内的早期抗原被显著识别。综上所述,这些结果突出了CD4(+)和CD8(+) T细胞对复杂病原体免疫优势的根本差异。